Marshall Wace, LLP Eye Point Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $7.75 Million - $11.6 Million	388,955 New	388,955 $8.04 Million
Q2 2023 Aug 14, 2023	BUY	$3.03 - $9.0 $125,111 - $371,619	41,291 Added 86.34%	89,115 $775,000
Q1 2023 May 15, 2023	BUY	$2.28 - $5.04 $66,924 - $147,939	29,353 Added 158.91%	47,824 $140,000
Q4 2022 Feb 14, 2023	BUY	$2.37 - $7.2 $43,776 - $132,991	18,471 New	18,471 $64,000
Q1 2022 May 16, 2022	SELL	$8.67 - $14.11 $100,641 - $163,788	-11,608 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.18 - $18.4 $266,084 - $480,939	-26,138 Reduced 69.25%	11,608 $142,000
Q2 2021 Aug 13, 2021	SELL	$8.69 - $11.08 $601,356 - $766,747	-69,201 Reduced 64.71%	37,746 $340,000
Q1 2021 May 17, 2021	BUY	$8.89 - $14.92 $950,758 - $1.6 Million	106,947 New	106,947 $1.09 Million

163

58.2M

224K

1.41M

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $272M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.